Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AJI Pharma USA
In Phase I of the study, escalating single doses of intravenous curdlan sulfate are tested. In Phase II, curdlan sulfate is administered daily for 7 days. (NOTE: Phase I is completed.)
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
HIV seropositivity.
No current AIDS-defining opportunistic infection, lymphoma, Kaposi's sarcoma, or other malignancy.
CD4 count \< 500 cells/mm3.
No critical illness that would shorten life expectancy to \< 16 weeks.
You may not be if
Concurrent Medication:
Excluded:
Antiretroviral or other experimental therapies.
Anticoagulants.
Steroids.
Cytotoxic or immunosuppressive agents.
Concurrent Treatment:
Excluded:
Radiotherapy.
Patients with the following prior condition are excluded:
History of heparin sensitivity.
Prior Medication:
Excluded within 1 month prior to study entry:
Antiretroviral or other experimental therapies.
Anticoagulants.
Steroids.
Cytotoxic or immunosuppressive agents.
Prior Treatment:
Excluded:
Radiotherapy within 1 month prior to study entry. Active IV drug abuse.
Clareo Health | Phase I/II Study of Curdlan Sulfate
